Is AOD-9604 Legal in Georgia?

What Is AOD-9604 and Why Does Its Legal Status Matter?

AOD-9604 is a synthetic 16-amino-acid fragment of human growth hormone (hGH), corresponding to amino acids 176 through 191 of the hGH sequence. Researchers have studied it primarily for fat metabolism and body-composition effects because it mimics the lipolytic region of hGH without the anabolic or insulin-sensitizing actions associated with full-length hGH. That narrower mechanism made it attractive as a potential obesity drug in the early 2000s.

The METAOD Trial and What It Showed

The key Phase IIb trial (METAOD, N=300) evaluated oral AOD-9604 at doses ranging from 1 mg to 54 mg daily over 12 weeks in adults with obesity. The trial did not meet its primary endpoint for statistically significant weight loss versus placebo. Because of that failure, the drug's developer, Metabolic Pharmaceuticals, did not pursue a New Drug Application (NDA) with the FDA. That history matters legally: AOD-9604 has never received FDA approval for any indication in humans. [1]

Why Legal Status Varies by Jurisdiction

A substance that is neither FDA-approved nor a controlled drug schedule falls into a regulatory gap that is filled differently depending on whether federal compounding rules, state pharmacy board rules, or research exemptions apply. Georgia residents face all three layers simultaneously, which is why a simple yes-or-no answer to "is AOD-9604 legal here?" requires unpacking each layer.

The Federal Framework: FDA Authority Over Compounding

The FDA regulates pharmacy compounding under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act). Both sections are directly relevant to AOD-9604.

Section 503A: Traditional Compounding Pharmacies

Section 503A allows state-licensed pharmacies to compound drugs for individual patients based on a valid prescription. However, the FDA maintains a "do-not-compound" list (also called the Category 1 list) of drug substances that present safety or effectiveness concerns, and a positive list of bulk drug substances that may be used in compounding. [2]

AOD-9604 was nominated as a bulk drug substance for the 503A list and evaluated by the FDA. As of the most recent published FDA decisions, AOD-9604 was placed in Category 2, meaning the FDA did not place it on the list of bulk substances that may be used in 503A compounding. The FDA's reasoning cited insufficient clinical evidence of safety and effectiveness in humans. Pharmacies operating under 503A in Georgia therefore cannot legally compound AOD-9604 for patient dispensing under that framework without risking enforcement action. [3]

Section 503B: Outsourcing Facilities

Section 503B outsourcing facilities can produce large batches of compounded drugs without individual patient-specific prescriptions, but they are limited to bulk substances on the FDA-approved 503B list (the Bulk Drug Substances Under Evaluation list, or BHCS list). AOD-9604 does not appear on the current 503B BHCS list. That means outsourcing facilities also cannot lawfully manufacture AOD-9604 for clinical use in Georgia or any other U.S. State. [4]

What "Gray Zone" Actually Means Here

When practitioners or websites describe AOD-9604 as a "gray-area peptide," they typically mean it is not a scheduled controlled substance under the DEA's Controlled Substances Act. That is true. Being unscheduled, however, does not confer permission to compound or dispense it as a drug. The absence of a schedule-listing is different from the presence of FDA approval or compounding authorization. Clinicians who conflate the two distinctions expose themselves and their patients to regulatory risk.

Georgia State Law: What the State Adds (and Doesn't Add)

Georgia pharmacy and medical-practice law does not contain a statute that names or specifically restricts AOD-9604. The Georgia State Board of Pharmacy (GSBP) enforces compounding standards that mirror federal USP Chapter 795 (non-sterile) and Chapter 797 (sterile) guidelines. [5] A licensed Georgia pharmacy that attempted to compound AOD-9604 peptide injections would face scrutiny under both GSBP rules and the federal FD&C Act simultaneously.

Georgia Medical Practice Act

The Georgia Composite Medical Board (GCMB) governs physician prescribing. Physicians licensed in Georgia may prescribe drugs off-label when medically justified, but they cannot prescribe a substance that no licensed pharmacy can legally dispense. Off-label prescribing authority and compounding authorization are independent legal questions. A Georgia physician writing an AOD-9604 prescription does not automatically make dispensing lawful if the compounding of that substance conflicts with FDA policy. [6]

No State-Level GRAS or Food-Ingredient Exemption

Some advocates cite the Australian Therapeutic Goods Administration (TGA) designation of AOD-9604 as a food ingredient (2014) to argue it is freely available. Georgia, like all U.S. States, operates under FDA jurisdiction for food and drug classification, not TGA rules. The FDA has not issued a parallel GRAS (Generally Recognized as Safe) determination for AOD-9604 as a food ingredient in the United States. That Australian designation has no legal effect on access in Georgia.

Research Use: A Narrow but Real Pathway

AOD-9604 may be obtained legally in the United States for legitimate in-vitro laboratory research or veterinary research without a human prescription. Research chemical suppliers can sell it labeled "not for human use" to verified research institutions. This pathway carries strict conditions.

Conditions for Legal Research Purchase

• The purchaser must be a legitimate research institution or licensed laboratory.
• The substance must not be administered to humans outside of an FDA-authorized Investigational New Drug (IND) application.
• Selling research-grade AOD-9604 to an individual who intends to inject it is not protected by the research-chemical exemption, regardless of what the seller's label states.

Patients who order injectable AOD-9604 from online suppliers under the pretense of "personal research" are buying an unapproved drug and face potential legal exposure, even if the act of simple possession is unlikely to be prosecuted absent other evidence of distribution.

How Telehealth and Anti-Aging Clinics Manage This

Some telehealth platforms operating in Georgia market AOD-9604 as part of weight-loss or anti-aging protocols. The legal strategies they use vary in their defensibility.

IND-Exempt Research Protocols

A small number of academic or IRB-supervised clinical programs may access AOD-9604 under an FDA IND application. Outside that setting, the IND pathway is not available to standard clinical practices.

Peptide Stacking and Substitute Compounds

Some clinics substitute FDA-listed peptides (for example, CJC-1295 or ipamorelin, which have had different compounding histories) for AOD-9604 specifically. The FDA's November 2023 guidance placed several peptides on the 503A do-not-compound list, so practitioners must check the current FDA bulk-substances list before prescribing any peptide compound. [7]

The HealthRX Georgia Peptide Access Framework

HealthRX's medical team has developed an internal decision framework for Georgia patients asking about AOD-9604 and related peptides:

1. Step 1, Confirm federal list status. Check the FDA's current 503A Category 1 and Category 2 lists before any prescribing discussion.
2. Step 2, Confirm pharmacy capacity. Identify whether a GSBP-licensed 503A pharmacy will accept and fill the compound; if none will, prescribing is moot.
3. Step 3, Evaluate alternatives. If AOD-9604 is inaccessible, consider FDA-approved agents with overlapping mechanisms. Semaglutide 2.4 mg (Wegovy) produced 14.9% mean body weight reduction at 68 weeks in STEP-1 (N=1,961) versus 2.4% with placebo (P<0.001). [8]
4. Step 4, Document medical rationale. Any off-label or compounded prescription requires thorough documentation of the clinical rationale in the patient record per GCMB guidelines.
5. Step 5, Revisit quarterly. FDA peptide compounding policy has changed multiple times since 2021; policy review should occur at least every 90 days.

Alternatives Available to Georgia Patients Right Now

Because AOD-9604 compounding is restricted federally, Georgia patients seeking body-composition or weight-loss support have several legally accessible options.

FDA-Approved GLP-1 Receptor Agonists

Semaglutide (Ozempic for type 2 diabetes; Wegovy for chronic weight management) and tirzepatide (Mounjaro for type 2 diabetes; Zepbound for weight management) are FDA-approved, can be prescribed by Georgia-licensed physicians, and can be dispensed by any licensed Georgia pharmacy. The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced a mean 20.9% body-weight reduction at 72 weeks versus 3.1% with placebo. [9]

Compounded Semaglutide (During Shortage)

The FDA placed branded semaglutide on the drug-shortage list in 2022, permitting 503A and 503B pharmacies to compound semaglutide temporarily. As of mid-2025, FDA has declared the shortage resolved for certain presentations, meaning compounded semaglutide's legal status is again in flux. Georgia patients should confirm current shortage status with their prescribing physician before ordering compounded semaglutide. [10]

Tesamorelin

Tesamorelin (Egrifta) is an FDA-approved growth hormone-releasing factor analog indicated for HIV-associated lipodystrophy. Some practitioners use it off-label for general fat reduction. Because it is FDA-approved, it can be prescribed and dispensed lawfully in Georgia through standard pharmacy channels, without relying on compounding authorization.

What Georgia Patients Should Ask Their Provider

Before starting any peptide protocol, Georgia patients should ask the following directly:

• "Is the peptide you are prescribing on the FDA 503A permitted list or the 503B BHCS list?"
• "Which specific pharmacy will fill this, and is that pharmacy GSBP-licensed?"
• "Has your clinic received any FDA warning letters related to peptide compounding?"
• "Is there an FDA-approved alternative that has demonstrated efficacy in a randomized controlled trial?"

The Endocrine Society's 2019 clinical practice guideline on growth hormone use in adults states: "We recommend against the use of growth hormone or its fragments in healthy adults for anti-aging, body composition improvement, or athletic enhancement outside of approved indications and clinical trials." [11] AOD-9604 is a fragment of growth hormone; that guidance applies directly.

FDA Enforcement Trend: Why This Matters in 2025

The FDA issued a guidance document in October 2023 addressing bulk drug substances nominated for 503A compounding, explicitly listing peptides under active review. Several compounds that had been informally available for years (including BPC-157, TB-500, and others) received formal do-not-compound status. [7] AOD-9604 was evaluated in this same review cycle. Georgia compounding pharmacies that continue to dispense Category 2 peptides risk FDA warning letters, injunctions, and state board reciprocal action from the GSBP.

The FDA's track record on enforcement has accelerated. Between 2020 and 2024, the agency issued more than 60 warning letters related to unapproved peptide compounding, a rate roughly three times higher than the preceding four-year period, based on the FDA's publicly available warning-letter database. [12]

Importing AOD-9604 Into Georgia: Personal-Use Importation Policy

Some patients consider purchasing AOD-9604 from international suppliers, citing the FDA's informal personal-use importation policy. That policy allows border officials to exercise discretion for small quantities of drugs imported for personal use when no approved U.S. Equivalent exists and the drug poses no public health risk.

AOD-9604 does not meet the standard conditions for this policy cleanly because: (a) the FDA has actively evaluated and declined to list it for compounding, signaling a safety and effectiveness concern, and (b) injectable peptides cross additional scrutiny as sterile products. Relying on personal-use importation for injectable AOD-9604 represents a meaningful legal and safety risk. The FDA retains authority to seize imported unapproved new drugs. [13]